Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

On the left is the latest issue of The Spectator U.S. edition. On the right is a screen shot from the home page of the American Spectator magazine.

The U.S. version of the Spectator, the world’s oldest English-language magazine, is being sued by the American Spectator Foundation for trademark infringement around its name, sources tell Axios.

Why it matters: Until this lawsuit, sources say the two titles had an amicable relationship for the past four decades.

  • The Spectator has been selling its U.K. magazine in the U.S. for over 100 years. In 2019 it launched a U.S. print version, a year after launching its U.S. digital site.
  • The American Spectator, which is now just a digital magazine, has undergone a few iterations since its inception in 1967. The conservative news magazine is run by The American Spectator Foundation.

Details: The American Spectator Foundation is suing The Spectator for entering the U.S. market, both in print and online, with a name and logo that's similar to its own publication. The lawsuit demands that The Spectator pay the American Spectator Foundation for damages caused by the branding confusion, among other things.

  • "Prior to entering the U.S. market, Spectator Ltd. was aware of "The American Spectator" mark and its use on magazines and other publications and in connection with a website," the lawsuit says.
  • "Despite its knowledge of "The American Spectator" mark and its use in the United States for decades, Spectator Ltd. elected to enter the U.S. market with a competing magazine and website under the confusingly similar marks Spectator USA, The Spectator U.S. Edition, and The Spectator."

In a statement provided to Axios, The Spectator says it had discussed its plans to launch in America with The American Spectator's editor, R. Emmett Tyrrell Jr., and others at the foundation in advance of its U.S. launch.

  • "Given our longstanding presence in America and that amicable relationship, we were surprised when The American Spectator decided to pursue us through the courts," the statement says.

Be smart: The two outlets don't have similar content, just similar names. The Spectator is less ideological, more global and covers more arts and culture. The American Spectator has long focused on political analysis in America through a conservative viewpoint.

Go deeper

Biden explains justification for Syria strike in letter to Congress

Photo: Chris Kleponis/CNP/Bloomberg via Getty Images

President Biden told congressional leadership in a letter Saturday that this week's airstrike against facilities in Syria linked to Iranian-backed militia groups was consistent with the U.S. right to self-defense.

Why it matters: Some Democrats, including Sens. Tim Kaine (D-Va.) and Chris Murphy (D-Conn.) and Rep. Ro Khanna (D-Calif.), have criticized the Biden administration for the strike and demanded a briefing.

5 hours ago - Health

FDA authorizes Johnson & Johnson's one-shot COVID-19 vaccine for emergency use

Photo: Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration on Saturday issued an emergency use authorization for Johnson & Johnson's one-shot coronavirus vaccine.

Why it matters: The authorization of a third coronavirus vaccine in the U.S. will help speed up the vaccine rollout across the country, especially since the J&J shot only requires one dose as opposed to Moderna and Pfizer-BioNTech's two-shot vaccines.

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios